Upfront Cash ($M)

Upfront Equity ($M)

Upfront Share (%)

Bicyclic peptides for dementia with option to jointly launch company to develop identified compounds

Evaluation of 5F9 combined with rituximab and acalabrutinib for Large B-cell lymphoma

Kinase, Immuno-Oncology

Co-Development, Co-Promotion, Equity, License, Option, Research

Kidney Genome Atlas to identify and validate targets for diabetic nephropathy, rare kidney diseases

$54M to support development of the KGA platform for DKD | $1.95 billion in research, development, regulatory and commercial milestones for the first five programs

Fully human antibody therapies for multiple oncology and immunology therapeutic targets

Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer

ICON-2 antibody-drug conjugate targeting tissue factor to treat solid tumors

Pegasus drug discovery platform to advance small molecule protein degraders against multiple targets

$70M upfront including an equity investment | Kymera is eligible to receive in excess of $1 billion in research, development, regulatory, and commercial milestones for up to six programs | tiered royalties

Tiered royalties in the mid-to-high single digit range | Ligand will receive an upfront license fee, and is eligible to receive over $76M of milestone payments

NexoBrid topical wound healing product for severe burns in North America

Tiered royalties ranging from high single-digit to low double-digit percentages | $7.5M upon U.S. BLA approval

Calpain 3 (CAPN-3) gene therapy for Limb-girdle muscular dystrophy type 2A

ND021 PD-L1/4-1BB/HSA monovalent tri-specific scMATCH3 for cancer in China, South Korea, Singapore

tumor necrosis factor (TNF) receptor superfamily member 9 (TNFRSF9) (CD137) (4-1BB), programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)

CStone will fund the research and development of ND021 up to completion of an initial Phase Ib clinical trial

$2M in Onconova shares purchased at a premium | HanX will place $2M in escrow in local currency for rigosertib clinical development expenses in China | Tiered royalties up to double digits | $45.5M in regulatory, development. and sales milestones

Navacim therapeutics for inflammatory bowel disease, autoimmune liver diseases and celiac disease

Autoimmune/Inflammatory, Gastrointestinal, Liver & Gallbladder Diseases

IBD - Crohn's Disease, IBD - Other, IBD - Ulcerative Colitis, Other Autoimmune/Inflammatory, Other Liver & Gallbladder Diseases

SkySTAR platform to discover small molecules RNA splicing modifiers for neurodegenerative diseases

Vonoprazan for acid-related disorders and H. pylori in the US, Europe and Canada

Up to five engineered oncolytic vaccinia virus candidates for immuno-oncology indications

$3M in preclinical milestones | Undisclosed option payment, plus additional development and commercial milestones for each product

Therapy Acceleration Program funds to develop mavorixafor in Waldenstrom’s macroglobulinemia

Masked antibody combined with pyrrolobenzodiazepine cytotoxic payload technology for solid tumors

RNAi therapeutics for ophthalmic & CNS indications, programs targeting genes expressed in the liver

Central Nervous System, Liver & Gallbladder Diseases, Ophthalmic

Broad Focus Central Nervous System, Broad Focus Ophthalmic

4.44 million common shares @ $90.00/sh | For each program, Alnylam will receive $2.5M at program initiation and an additional $2.5 million at lead candidate, for up to $30M in annual
discovery funding | $200M in near-term milestones for the eye and
CNS programs | $325M in sales milestones for cemdisiran | low double-digit to 20% royalty in Eye Field | $150M in agg milestones for Eye Field targets | 50% PS in CNS & Liver Fields

Evaluation of APG-1387 combined with Toripalimab for solid and hematological tumors in China

Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors

Atomnet AI-based screening technology to identify compounds for Chagas disease

Tiered royalties ranging from the mid-single to low-double digits | $405M per target for development, regulatory and commercialization milestones

Prolactin receptor antibody for hair loss, endometriosis, chronic disease indications

Genitourinary/Gynecologic, Other/Miscellaneous

BeiGene is responsible for all costs in Asia excluding Japan, Australia and New Zealand | Undisclosed early clinical milestones, plus up to $249M in additional development and regulatory milestones globally and commercial milestones

Expression systems to produce membrane protein targets for drug discovery

DMX-101 in utero protein replacement therapy for X- Linked Hypohidrotic Ectodermal Dysplasia

Combined genome editing and cell therapy technologies to discover cell medicines

Autoimmune/Inflammatory, Cancer, Cardiovascular, Central Nervous System

Phase I evaluation of WP1066 in children with recurrent or refractory malignant brain tumors

Phase I/II evaluation of CM-24 combined with nivolumab for non-small cell lung cancer

FCX-007 gene therapy for recessive dystrophic epidermolysis bullosa in the US

$75M consisting of $25M when FCX-007 achieves $250M in cumulative net sales and an additional $50M upon attaining $750M in cumulative net sales | Castle Creek will pay for all development and manufacturing expenses up to $20M prior to BLA filing with the FDA and is responsible for 70% of excess costs above the $20M. | $2.5M for the first patient enrolled in the Phase 3 clinical trial and $30M upon BLA approval and commercial readiness. | Fibrocell will receive a 30% share of the gross profits from FCX-007 sales.

Blacksmith metalloenzyme chemistry platform to identify antibiotics against two targets

Losmapimod p38 kinase inhibitor for facioscapulohumeral muscular dystrophy

mitogen-activated protein kinase 14 (MAPK14) (p38) (p38-alpha) (p38MAPK)

Indivutype database combined with PanHunter bioinformatics analysis platform for colorectal cancer

Co-Development, Co-Promotion, License, Option, Research

Insitro Human platform to create disease models of NASH and identify up to five targets

Low double-digit tiered royalties | Near term payments up to $35M based on operational milestones | $200M in development, regulatory and commercial milestones for each of the five Gilead targets

Four programs including TCR immunotherapy targeting NY-ESO-1 & DC vaccine targeting WT-1 and PRAME

Cytovant will reimburse all R&D costs incurred by Medigene | Low double-digit royalties | Development, regulatory, and commercial milestones in excess of $1 billion for the four products across multiple indications

MT-1303 (amiselimod) for IBD, ulcerative colitis, autoimmune diseases WW ex-Japan

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, China, India, New Zealand, Other Asian, Southeast Asia

Immunosuppresant

Polymyxin antimicrobials including colistin for drug-resistant gram-negative pathogens

AT702 AAV-antisense candidate for Duchenne muscular dystrophy and myotonic dystrophy

DNA/RNA Disruption

Pulmazole (inhaled iSPERSE formulation of itraconazole) for allergic bronchopulmonary aspergillosis

DNA/RNA Disruption

Tiered low double digit to mid teen royalties | $226M in development, regulatory and commercial milestones

Phase Ib/II evaluation of TT12 cell therapy combined with Keytruda in cervical cancer

Cell Therapy, Immuno-Oncology

AI-based discovery technology to identify drug candidates for lung cancer

Microfluidic screening technology to discover modulatory and functional antibodies against GPCRs

ABY-039 anti-FcRn Affibody for rare Immunoglobulin G-mediated autoimmune diseases

Tiered low double-digit royalties | $625M in development and sales milestones

Expanded Genetic Code platforms to discover biologic drug candidates for cancer

Ambrx will receive $19M if BeiGene elects to initiate additional programs, and up $446M in development, regulatory, and sales-based
milestones for all programs

Double digit royalties to mid-20s, per Aslan's 2018 20-F | $8M in agg milestones, per Aslan's 2018 20-F

Trastuzumab deruxtecan (DS-8201) antibody-drug conjugate for HER2-positive cancers WW ex-Japan

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, China, India, New Zealand, Other Asian, Southeast Asia

DNA topoisomerase I, epidermal growth factor receptor type 2 (HER2) (ERBB2) (receptor tyrosine-protein kinase erbB-2)

$1.35 billion half of which is due upon execution, with the remainder payable 12 months later | $3.8 billion in regulatory milestones

REAL database to support drug discovery and identify hit series in multiple research programs

Funding to advance oncology therapeutics based on TargetAlloMod drug discovery platform

Centaur Chemist AI-based platform to discover small molecules for cancer and autoimmune indications

DNA encoded chemical libraries to discover small molecule leads against dermatology targets

DNA encoded chemical libraries to discover small molecule leads against undisclosed targets

Tilsotolimod (TLR agonist) with Yervoy (ipilimumab) and Opdivo (nivolumab) for solid tumors

toll-like receptor 9 (TLR9), cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (CD152)

Generative modelling artificial intelligence technology for three drug discovery projects

Preclinical target to treat autoimmune disorders by regulating immune cell metabolism

Tiered royalties ranging from the mid-single to low-double digits | $565M in development and commercialization milestones,

China National Biotec Group, Lanzhou Institute of Biological Product

Portfolio of bone disease biotherapeutics including blosozumab for osteoporosis in China

Schizophyllan delivery technology to develop oligonucleotide therapeutic for undisclosed indications

Spin out of Wings Therapeutics to develop RNA therapies for dystrophic epidermolysis bullosa

Serabelisib & two PI3Kalpha-specific inhibitors for all indications ex-undisclosed rare diseases

Trianni Mouse monoclonal antibody discovery platform to support HIV vaccine research

AI-platform to identify drug candidates for undisclosed neurological disease

VTX-801 gene therapy for Wilson disease, acquisition of 15% equity stake with option to acquire 100%

Liver & Gallbladder Diseases, Other/Miscellaneous

Genetic Disorders, Other Liver & Gallbladder Diseases

€45 million (US$51 million) | €560 million (US$635.8 million) inclusive of the option exercise payment and clinical, regulatory, and commercial milestones

Subcutaneously delivered peptide therapies against up to four complement pathway targets

$495M in sales milestones for lead target | High single- to low double-digit royalties | $115M in development milestones for lead target | Option fee of $15 million for each of the three subsequent targets, plus additional development and sales milestones and royalty payments at a reduced price to the lead target.

TVB-2640 (ASC40) FASN inhibitor for non-alcoholic steatohepatitis in China

Single-cell screening technology to discover mAbs against up to 10 targets

DiversImmune antibody platform to generate bispecific therapeutics for immuno-oncology indications

$60 million in near-term R&D funding | Abpro eligible to receive up to $4 billion

epidermal growth factor receptor (EGFR) (ERBB) (ERBB1) (HER1) (PIG61) (mENA), epidermal growth factor receptor type 2 (HER2) (ERBB2) (receptor tyrosine-protein kinase erbB-2)

Double digit royalties up to mid-20s, per Aslan's 2018 20-F | $11M in agg milestones, per Aslan's 2018 20-F

Double-digit royalties to low 20s, per Dermira's 3Q19 | $50M option exercise fee; $30 upon initiation of certain Phase 3 clinical studies and up to $85 upon the achievement of regulatory milestones and the first commercial sale of lebrikizumab in Europe. | CON sales milestones

FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) for prostate cancer

Africa, Asia, Europe, NAFTA, South America

All African Countries, All European Countries, All South American Countries, Australia, Canada, India, Mexico, New Zealand, Other Asian, Southeast Asia

Spinout of IFM Due to develop cGAS/STING antagonists for inflammatory and autoimmune diseases

€300 million (US$342M) | Up to €500 million (US$570M) in development milestone payments related to data from the M7824 lung cancer program | Up to €2.9 billion (US$3.3 billion) in approval and commercial milestones

MOB-015 topical formulation of terbinafine for onychomycosis in Europe

EUR 1.5 million | EUR 50 million (US$56M) in milestone payments, including EUR 1.5 million (US$1.7M) paid at signing

Undisclosed upfront payment and research funding, and development, clinical and commercial milestones totaling over $725M.

Myeloproliferative Neoplasm Research Consortium, Mount Sinai

transforming growth factor (TGF) beta 1 (TGFB1), transforming growth factor (TGF) beta 3 (TGFB3)

CRADA to evaluate Bryostatin-1 in Phase I trial for leukemia and B-cell lymphoma

Spinout of Anthos to develop MAA868 anti-Factor XI/XIa antibody for cardiovascular diseases

Joint venture to develop RMX1001, RMX1002, RMX2001, HH185 and CDK4/6i

Autoimmune/Inflammatory, Central Nervous System, Infectious-Bacterial

Osteoarthritis, Pain, Rheumatoid Arthritis, Tuberculosis

Enzyme Inhibitor, Receptor, Antibacterial

Spin out of Inexia to develop preclinical intranasal small molecule orexin agonists for narcolepsy

Spin out of Orexia to develop oral small molecule orexin agonists for narcolepsy

Integrated drug discovery program against G Protein-Coupled Receptor target

$3.4M grant to support Phase I/II trial of SX-682 in myelodysplastic syndrome

Five AAV gene therapy products for rare monogenic CNS diseases, option to additional programs

Macrophage checkpoint modulator antibodies for all human oncology indications in China

AAV gene therapy to pathological species of alpha-synuclein for Parkinson's

$500M in agg sales milestones, per Voyager's 2/21/19 8-K | Mid-single digit royalty, per Voyager's 2/21/19 8-K | $80M for Research Compound, $75M on licesnse option exercise, plus $450M in dev/reg milestones for Parkinson's, per Voyager's 2/21/19 8-K | $30M for each of 3 add'l Research Compounds, plus $185M in dev/reg milestones for non-Parkinson's indication, per Voyager's 2/21/19 8-K

Co-Development, Co-Promotion, License, Option, Research

$160M in development milestones for the XmAb24306 program, per Xencor's 3Q19 | $180M in development milestones for each new IL-15 drug candidate, per Xencor's 3Q19 | 45% PS, per Xencor's 3Q19 | Xencor pays 100% of Initial Studies & 45% of dev costs after Initial Studies

Expanded rights to AlivaMab Mouse platform for discovery of antibody-based therapeutics

TruTCR platform to develop neoantigen directed T-cell therapies for cancer

Development, regulatory and commercial milestones in excess of $2 billion